InMed Pharmaceuticals (NASDAQ:INM) Issues Quarterly Earnings Results

InMed Pharmaceuticals (NASDAQ:INM) issued its quarterly earnings data on Wednesday. The company reported ($3.64) EPS for the quarter, Zacks reports. InMed Pharmaceuticals had a negative return on equity of 65.74% and a negative net margin of 137.41%.

InMed Pharmaceuticals Stock Performance

Shares of INM opened at $3.20 on Thursday. InMed Pharmaceuticals has a one year low of $2.41 and a one year high of $15.70. The stock has a 50-day moving average price of $4.35 and a 200 day moving average price of $4.73. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.07 and a quick ratio of 4.22.

About InMed Pharmaceuticals

InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry.